Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...
Abecma (idecabtagene vicleucel) is prescribed to treat multiple myeloma in certain cases. The drug comes as a suspension (liquid mixture) made from your body’s cells. You receive it by ...
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...
BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...
The global trial was designed to evaluate Abecma, a CAR-T cell therapy, with lenalidomide, a multiple myeloma therapy marketed by Bristol Myers (BMY) as Revlimid, versus lenalidomide monotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback